Open AccessInfeksjonsrisiko ved bruk av selektivt immunmodulerende midler mot revmatoid artritt
Author(s) -
Erna Harboe,
Jan Kristian Damås,
Roald Omdal,
Stig S. Frøland,
Haakon Sjursen
Publication year - 2012
Publication title -
tidsskrift for den norske lægeforening
Language(s) - Norwegian
Resource type - Journals
SCImago Journal Rank - 0.162
H-Index - 29
eISSN - 0807-7096
pISSN - 0029-2001
DOI - 10.4045/tidsskr.12.0180
Subject(s) - medicine , rituximab , rheumatoid arthritis , tuberculosis , immunology , disease , incidence (geometry) , mycobacterium tuberculosis , antibody , pathology , physics , optics
New drugs for rheumatoid arthritis (RA) have resulted in an improvement in patients' functioning and morbidity, but are linked with increased risk of infections. Traditional immunosuppressant drugs are often used in combination with anti-tumour necrosis factor-alpha (TNF-α) inhibitors or anti-CD20 (rituximab).